Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

251 - 260of 392 News

January 31, 2020

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer

January 30, 2020

Not intended for U.S. and UK Media - Updated results of Phase III trial show:

Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer

January 23, 2020

Not intended for U.S. and UK Media

Bayer receives approval for darolutamide in Japan

January 13, 2020

Not intended for U.S. and UK Media

Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®

December 10, 2019

Bayer to significantly step-up its sustainability efforts

December 10, 2019

Bayer to significantly step-up its sustainability efforts

November 29, 2019

Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets

November 25, 2019

Not intended for U.S. and UK Media

Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism

November 18, 2019

Not intended for U.S. and UK Media

Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint

November 07, 2019

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer refinances 1.75 billion euro hybrid bond

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk